Baldwin Wealth Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Baldwin Wealth Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,000	Closed	-$84K	–	526
2019 Q2	$84K	Hold	1,000	–	–	0.01%	258
2019 Q1	$96K	Hold	1,000	–	–	0.01%	244
2018 Q4	$71K	Hold	1,000	–	–	0.01%	254
2018 Q3	$85K	Hold	1,000	–	–	0.01%	268
2018 Q2	$116K	Hold	1,000	–	–	0.02%	240
2018 Q1	$81K	Hold	1,000	–	–	0.01%	255
2017 Q4	$59K	Hold	1,000	–	–	0.01%	285
2017 Q3	$47K	Hold	1,000	–	–	0.01%	295
2017 Q2	$36K	Hold	1,000	–	–	0.01%	326
2017 Q1	$31K	Buy	+1,000	New	+$31.1K	0.01%	334

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Baldwin Wealth Partners's ENTA Position: Q3 2019 in Review

Baldwin Wealth Partners sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 1,000 shares — an estimated $84K sold.

Baldwin Wealth Partners first reported a position in ENTA in Q1 2017 and held it in 10 quarters. The position peaked at $116K in Q2 2018. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Baldwin Wealth Partners reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Baldwin Wealth Partners sold 1,000 Enanta Pharmaceuticals shares in Q3 2019, an estimated $84K.
Baldwin Wealth Partners first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 10 quarters.
Baldwin Wealth Partners's Enanta Pharmaceuticals position peaked at $116K in Q2 2018.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Baldwin Wealth Partners's 13F filing for Q3 2019, filed 10 Oct 2019.